Cleveland, OH, June 27, 2019 – Edgewater Capital Partners (“Edgewater“), the performance materials focused private equity firm, announced today that Brian Scanlan has joined the firm as an Operating Partner. He will work closely with Edgewater’s transaction team to develop investment opportunities in Life Sciences. Focus will be on businesses that offer differentiated technologies, manufacturing capabilities, products or service offerings within the pharmaceutical, biopharma, nutritional, or consumer health sectors. Brian’s addition coincides with Edgewater closing its most recent fund, ECP IV, at $185 million.

Brian has spent nearly three decades in the pharmaceutical services sector, and has been engaged with several Edgewater portfolio companies in advisory roles including as a non-executive Director at Callery. He is also the Founder and Managing Partner of Freedom Bioscience Partners, a consultancy firm focused on M&A and strategic business advisory to the pharmaceutical and fine chemical industries. Prior to launching Freedom, Brian served as Chief Executive Officer at Cambridge Major Laboratories, a global pharma contract development and manufacturing organization (CDMO) focused on active pharmaceutical ingredients, solid state chemistry, and analytical services. For his entire career, he has developed and grown companies offering highly differentiated technologies and services.

Bob Girton, Partner at Edgewater, commented, “Brian’s experience expands our deep industry-specific expertise, and our ability to see opportunity where others might see risk, such as regulatory or operational topics that often exist in the Life Science sector. Also, Brian will help our portfolio companies enhance their value proposition to their customers through identifying and guiding thoughtful investment in people, capabilities, and technology. The end result is our investments will accelerate organic growth along with targeted add-on acquisitions.

Brian Scanlan added, “I’m excited to formally join the team after working closely alongside Edgewater and many of its portfolio companies in a variety of roles over the past three years. I’m impressed by the exceptional track record, the culture, and the strong partnerships created between Edgewater and its portfolio. Looking forward to putting Fund IV to work in the Life Science sector.”

About Edgewater Capital Partners

Edgewater is a Cleveland based, sector-focused private equity firm making investments in middle and lower middle-market performance materials businesses, specifically specialty chemicals, life sciences, and engineered components and materials verticals. For additional information on Edgewater, visit the firm’s website at or email at